Our Development Pipeline - Innovative Drugs

Our Development Pipeline - Generic Drugs

Uni-Bio entered a joint-research agreement with Sunshine-Novo to co-develop chemical drugs under the Chemical manufacturing controls (CMC) route. 

Acarbose is a small molecule drug used to treat diabetes mellitus type 2 and, in some countries, prediabetes. Acarbose inhibits a class of enzymes, known as glycoside hydrolases, required for digesting carbohydrates into glucoses. With the inhibition of enzyme, the patient would effectively absorb less glucose because the carbohydrates are not broken down into glucose molecules. For patients with Type II Diabetes, the therapeutic effect of Acarbose decreases blood glucose levels, achieving a reduction in HbA1c levels.


Uni-Bio Science is committed to creating novel high-value, patented drugs via its in-house R&D capabilities.

Uni-Bio Science's growing pipeline of drug candidates is focused on addressing unmet medical needs in the areas of diabetes, ophthalmology, and dermatology.

The Company's Research & Development team of highly-trained specialists focuses on the development of complex, next-generation biologics and small-molecule drugs. The team has a strong track record in clinical development and regulatory expertise.

Uni-Bio Science is one of the leading regional biotech players with a track record in successfully developing new drugs through its clinical pipeline.